Jefferies downgraded Alnylam (ALNY) to Hold from Buy with a price target of $330, down from $522, after assuming coverage of the name. The firm is “impressed” with the company’s RNAi platform but says the shares are “priced to perfection.” Alnylam’s longer term consensus expectations are at risk as they price in big market growth and low competition, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Tenaya Therapeutics enters research collaboration with Alnylam
- Alnylam Grants CEO New Performance-Based Equity Award
- Alnylam’s KARDIA-3 Hypertension Trial Reaches Completion, Raising Key Questions for ALNY Investors
- Balancing Short-Term Amvuttra Headwinds Against Solid TTR Growth: Rationale for Maintaining a Hold Rating
- Alnylam’s New Phase 1 ALN-4285 Trial: What Early Safety Data Could Mean for ALNY Investors